Financials in USD. Standardized financial statements.
A compact view of how Global Blood Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $194.75M | $123.80M | $2.11M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +57.3% | +5773.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.32M | $1.99M | $48,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $191.43M | $121.82M | $2.06M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +98.3% | +98.4% | +97.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $479.12M | $365.97M | $291.64M | $182.74M | $119.25M | $83.13M | $46.39M | $20.18M | $15.16M |
| Operating Income? | -$287.15M | -$243.17M | -$281.28M | -$182.74M | -$119.25M | -$83.13M | -$46.39M | -$20.51M | -$15.66M |
| EBITDA? | -$278.53M | -$226.92M | -$256.83M | -$169.59M | -$115.37M | -$81.23M | -$45.49M | -$20.14M | -$17.58M |
| Income Before Tax | -$302.61M | -$247.55M | -$266.77M | -$174.19M | -$117.02M | -$82.47M | -$46.36M | -$20.81M | -$18.12M |
| Income Tax Expense | $477,000 | $0 | $0 | $0 | $0 | $659,000 | $33,000 | $0 | $0 |
| Net Income? | -$303.09M | -$247.55M | -$266.77M | -$174.19M | -$117.02M | -$82.47M | -$46.36M | -$20.81M | -$18.12M |
| EPS? | $-4.82 | $-4.04 | $-4.57 | $-3.41 | $-2.76 | $-2.48 | $-3.62 | $-1.51 | $-0.83 |
| Diluted EPS? | $-4.82 | $-4.04 | $-4.57 | $-3.41 | $-2.76 | $-2.48 | $-3.62 | $-1.51 | $-0.83 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality